ACR 2022 How Does Risk for CV Events Differ Between Tofacitinib and TNFi in RA? Publish Date November 17, 2022 Results of the ORAL Surveillance study showed a higher risk for major adverse CV events and venous thromboembolism with tofacitinib vs TNFis.
